Guselkumab appears effective for psoriasis in real-world study

  • Galluzzo M & al.
  • J Clin Med
  • 9 Jul 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Guselkumab is associated with clinical improvement in patients with moderate-to-severe psoriasis, according to a small, retrospective study.

Why this matters

  • Real-world evidence of the effectiveness of biologics in psoriasis treatment is sparse.

Key results

  • At 12 months, guselkumab was associated with 84.2% of patients achieving a Psoriasis Area and Severity Index (PASI) score of ≤3.
  • 84.2% of patients achieved ≥75% improvement in the PASI score (PASI 75) at 12 months.
    • 78.9% achieved PASI 90.
    • 63.2% achieved PASI 100.
  • Previous biologic treatment was inversely associated (ORs) with:
    • PASI 75: 
      • 20 weeks: 2.85 (P=.004).
    • PASI 90:
      • 12 weeks: 1.96 (P=.017).
      • 28 weeks: 2.17 (P=.008).
    •  PASI 100:
      • 20 weeks: 2.86 (P=.002).
      • 28 weeks: 2.22 (P=.006).
      • 36 weeks: 2.04 (P=.013).
  • Comorbidities were inversely associated (ORs) with:
    • PASI 90: 
      • 20 weeks: 2.94 (P=.008).
      • 36 weeks: 5.26 (P=.015).
      • 44 weeks: 4.76 (P=.016).
    • PASI 100: 
      • 44 weeks: 3.33 (P=.012).
      • 52 weeks: 6.67 (P=.026).

Study design

  • 52 patients with moderate-to-severe psoriasis were treated with 100 mg of guselkumab and followed for 1 year.
  • Funding: None.

Limitations

  • Retrospective.
  • Small number of patients.